Pharmaceutical

Devimistat by Cornerstone Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of Approval

Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Soft Tissue Sarcoma.

Dec 24, 2023 - 18:00
Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Soft Tissue Sarcoma.
Read the original article

Tags:

Previous Article

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

Next Article

(Nanatinostat + valganciclovir) by Viracta Therapeutics for Solid Tumor: Likelih...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: House transparency, PBM reform bill gains bipartisan support

STAT+: House transparency, PBM reform bill gains bipart...

Sep 8, 2023

Activist investor Starboard cries foul play in exec U-turn at Pfizer

Activist investor Starboard cries foul play in exec U-t...

Oct 12, 2024

STAT+: Just how much money do drugmakers gain from patent extensions?

STAT+: Just how much money do drugmakers gain from pate...

Sep 26, 2023